Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023

Kezar Life Sciences, Inc.

Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.
Net loss for FY2022 was $68.2M ($1.01 per share) vs $54.6M ($1.04 per share) in 2021.
R&D expenses for FY2022 increased to $51.0M from $38.9M, driven by advancing zetomipzomib and KZR-261 programs.
PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis to initiate in H1 2023; PORTOLA Phase 2a in autoimmune hepatitis ongoing.
KZR-261 dose escalation currently enrolling Cohort 6; dose expansion study planned for H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.